CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases

In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more

CVS beat Wall Street expectations by a wide margin in the second quarter and raised its full-year profit forecast to as much as $8.10 per share